HHS awards $1.35B for vaccine manufacturing facility construction, with a 75-month duration

Contract Overview

Contract Amount: $1,349,853,665 ($1.3B)

Contractor: Seqirus Inc

Awarding Agency: Department of Health and Human Services

Start Date: 2009-01-15

End Date: 2029-09-30

Contract Duration: 7,563 days

Daily Burn Rate: $178.5K/day

Competition Type: FULL AND OPEN COMPETITION

Number of Offers Received: 2

Pricing Type: COST SHARING

Sector: Construction

Official Description: TAS::75 0140::TAS CONSTRUCTION OF VACCINE MANUFACTURING FACILITY

Place of Performance

Location: CAMBRIDGE, MIDDLESEX County, MASSACHUSETTS, 02139

State: Massachusetts Government Spending

Plain-Language Summary

Department of Health and Human Services obligated $1.35 billion to SEQIRUS INC for work described as: TAS::75 0140::TAS CONSTRUCTION OF VACCINE MANUFACTURING FACILITY Key points: 1. The contract's value suggests a significant investment in critical infrastructure. 2. The long duration indicates a complex, multi-phase construction project. 3. The cost-sharing payment type may imply shared risk and reward between the government and contractor. 4. The award was made under full and open competition, suggesting a robust bidding process. 5. The contractor, Seqirus Inc., has a substantial contract award, indicating its capacity for large-scale projects. 6. The project is located in Massachusetts, potentially impacting the regional construction labor market.

Value Assessment

Rating: good

The contract value of $1.35 billion for a vaccine manufacturing facility is substantial. Benchmarking this against similar large-scale construction projects for specialized facilities is challenging without more specific data on the facility's scope and capabilities. However, the cost-sharing nature of the contract suggests an attempt to align incentives and manage costs effectively. The long duration of over 6 years (7563 days) is typical for projects of this magnitude, allowing for phased development and potential adjustments.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

This contract was awarded under full and open competition, indicating that multiple bidders were likely solicited and evaluated. The presence of two bids suggests a competitive environment, though the exact number of proposals received is not specified. A competitive process generally leads to better price discovery and potentially more favorable terms for the government.

Taxpayer Impact: Full and open competition is beneficial for taxpayers as it encourages a wider range of potential contractors to bid, driving down costs and improving the quality of services through market forces.

Public Impact

The primary beneficiaries are likely the public, through enhanced vaccine manufacturing capabilities and potentially increased national biosecurity. The services delivered involve the construction of a specialized vaccine manufacturing facility. The geographic impact is concentrated in Massachusetts, where the facility will be built. Workforce implications include job creation in the construction sector in Massachusetts and potentially long-term employment in the advanced manufacturing and pharmaceutical industries upon facility completion.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Long contract duration (7563 days) could lead to cost overruns if not managed meticulously.
Cost-sharing arrangements require careful monitoring to ensure equitable distribution of costs and risks.
The specialized nature of a vaccine manufacturing facility may present unique construction challenges and risks.
Dependence on a single contractor for such a critical facility warrants close oversight.
Potential for scope creep over the extended project timeline.

Positive Signals

Awarded under full and open competition, suggesting a competitive pricing environment.
The significant investment indicates a commitment to bolstering domestic vaccine production capacity.
The contractor, Seqirus Inc., is a known entity in the biopharmaceutical space, suggesting relevant expertise.
The long duration allows for phased development and adaptation to evolving needs.
The cost-sharing model can incentivize efficient project management and cost control.

Sector Analysis

The construction of specialized facilities like vaccine manufacturing plants falls within the broader industrial construction sector. This contract represents a significant investment in advanced manufacturing infrastructure, particularly within the biopharmaceutical sub-sector. Comparable spending benchmarks would typically involve large-scale industrial or specialized facility construction projects, often involving government funding for critical national interests. The market for such specialized construction is often characterized by a limited number of highly qualified firms capable of undertaking complex projects.

Small Business Impact

The data indicates that small business participation was not a primary focus for this specific award, as the 'sb' (small business) flag is false and 'ss' (small business set-aside) is also false. There is no explicit mention of subcontracting goals for small businesses within the provided data. This suggests that the primary contractor, Seqirus Inc., will likely manage the majority of the construction, and opportunities for small businesses may be limited to direct supply or service contracts awarded by the prime contractor, rather than through set-aside provisions.

Oversight & Accountability

Oversight for this contract would primarily fall under the Department of Health and Human Services (HHS), specifically the Office of Assistant Secretary for Preparedness and Response (ASPR). Given the contract's value and duration, robust oversight mechanisms are expected, including regular progress reports, site inspections, and financial audits. Accountability measures would be tied to the contract's performance clauses and milestones. Transparency would be facilitated through contract award databases and potentially public reporting on project progress, though specific details on IG jurisdiction or detailed transparency measures are not provided.

Related Government Programs

Biopharmaceutical Manufacturing Facilities
National Biodefense and Countermeasures Initiatives
Public Health Infrastructure Investments
Advanced Manufacturing Construction Projects
Government-funded Research and Development Facilities

Risk Flags

Extended contract duration poses significant risk for cost escalation and obsolescence.
Cost-sharing requires careful monitoring to ensure equitable risk and cost distribution.
Specialized nature of facility may lead to unique construction challenges.
Potential for contractor performance degradation over a very long contract term.
Reliance on a single large award for critical infrastructure warrants close oversight.

Frequently Asked Questions

What is this federal contract paying for?

Department of Health and Human Services awarded $1.35 billion to SEQIRUS INC. TAS::75 0140::TAS CONSTRUCTION OF VACCINE MANUFACTURING FACILITY

Who is the contractor on this award?

The obligated recipient is SEQIRUS INC.

Which agency awarded this contract?

Awarding agency: Department of Health and Human Services (Office of Assistant Secretary for Preparedness and Response).

What is the total obligated amount?

The obligated amount is $1.35 billion.

What is the period of performance?

Start: 2009-01-15. End: 2029-09-30.

What is the historical spending pattern of the Department of Health and Human Services (HHS) on vaccine manufacturing facilities?

HHS has historically invested in vaccine manufacturing capabilities, particularly in response to public health emergencies and to bolster national biosecurity. While specific dollar amounts for vaccine manufacturing facility construction can vary widely based on project scope and timing, significant investments have been made over the years. These investments are often part of broader strategies to ensure a robust domestic supply chain for critical medical countermeasures. The current $1.35 billion award for a new facility indicates a substantial, long-term commitment to expanding or modernizing these capabilities, potentially reflecting lessons learned from past public health crises and a strategic focus on future pandemic preparedness. Detailed historical spending would require a comprehensive review of HHS's budget allocations and contract awards related to infrastructure over several fiscal years.

How does the cost-sharing arrangement in this contract compare to typical government construction contracts?

Cost-sharing arrangements in government contracts are less common for pure construction projects and more typical for research and development or complex system acquisition where risk and reward are shared. In this contract, the 'COST SHARING' payment type (PT) suggests that both the government and the contractor, Seqirus Inc., will bear a portion of the project costs. This differs from fixed-price contracts where the government pays a set amount, or cost-plus contracts where the government reimburses all allowable costs plus a fee. The specific terms of the cost-sharing (e.g., the percentage split, which costs are shared) are crucial for assessing value. This approach aims to incentivize the contractor to manage costs efficiently, as they have a direct financial stake in controlling expenditures. However, it requires rigorous oversight to ensure fair cost allocation and prevent potential disputes.

What is Seqirus Inc.'s track record with large-scale government construction projects?

Seqirus Inc. is primarily known as a global biopharmaceutical company specializing in influenza vaccines and treatments. While they have extensive experience in building and operating manufacturing facilities for pharmaceuticals, their direct track record as a prime contractor for large-scale *government construction projects* of this nature (i.e., managing the entire construction process from ground-up) may be limited. Their expertise likely lies in the design, engineering, and operational aspects of biomanufacturing facilities. It is probable that Seqirus Inc. will subcontract significant portions of the actual construction work to specialized construction firms. Therefore, assessing their track record should consider their experience in managing such complex projects, their ability to select and oversee competent construction partners, and their history of delivering facilities on time and within budget, rather than solely their direct construction execution capabilities.

What are the potential risks associated with the 7563-day (approximately 20.7 years) contract duration?

A contract duration of 7563 days (over 20 years) for a construction project is exceptionally long and presents several significant risks. Firstly, the risk of cost escalation due to inflation over such an extended period is substantial, even with cost-sharing mechanisms. Secondly, technological advancements in vaccine manufacturing could render the facility design or capabilities obsolete before or shortly after completion, requiring costly modifications. Thirdly, regulatory requirements and environmental standards are likely to evolve over two decades, necessitating compliance updates. Fourthly, contractor performance and stability over such a long timeframe can be uncertain; key personnel may leave, or the company's financial health could change. Finally, the extended timeline increases the potential for unforeseen geopolitical events, supply chain disruptions, or shifts in public health priorities that could impact the project's necessity or scope. Robust change management and contingency planning are critical.

How does the 'TAS CONSTRUCTION OF VACCINE MANUFACTURING FACILITY' align with broader federal strategies for pandemic preparedness?

This contract directly aligns with broader federal strategies aimed at enhancing pandemic preparedness and biosecurity. The COVID-19 pandemic highlighted vulnerabilities in domestic vaccine manufacturing capacity and supply chains. By awarding a substantial contract for the construction of a new vaccine manufacturing facility, the Department of Health and Human Services (HHS) is investing in critical infrastructure designed to ensure the nation can rapidly develop, produce, and distribute vaccines and other medical countermeasures during future health crises. This initiative supports goals such as reducing reliance on foreign manufacturing, shortening lead times for vaccine deployment, and maintaining a state of readiness. The long-term nature of the project underscores a strategic commitment to building resilient and scalable domestic production capabilities beyond immediate needs.

What is the significance of the 'MASSACHUSETTS' (ST) location for this vaccine manufacturing facility?

Locating a vaccine manufacturing facility in Massachusetts is significant due to the state's established strength as a hub for the biotechnology and pharmaceutical industries. Massachusetts boasts a rich ecosystem of research institutions, universities, skilled labor, and existing life sciences companies, which can foster collaboration, innovation, and access to a qualified workforce. Proximity to other biopharmaceutical entities can facilitate partnerships, supply chain integration, and knowledge sharing. Furthermore, the state often has supportive policies and infrastructure for the life sciences sector. This strategic location likely aims to leverage these existing advantages to accelerate the facility's development, operational efficiency, and long-term success, potentially contributing to the region's economic growth in the high-value life sciences sector.

Industry Classification

NAICS: Construction › Nonresidential Building Construction › Industrial Building Construction

Product/Service Code: RESEARCH AND DEVELOPMENT › DEFENSE (OTHER) R&D

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Solicitation ID: RFPHHSBARDA0809

Offers Received: 2

Pricing Type: COST SHARING (T)

Evaluated Preference: NONE

Contractor Details

Address: 475 GREEN OAKS PKWY, HOLLY SPRINGS, NC, 27540

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Foreign-Owned and U.S.-Incorporated Business, Manufacturer of Goods, Not Designated a Small Business, Special Designations

Financial Breakdown

Contract Ceiling: $2,211,158,281

Exercised Options: $1,349,853,665

Current Obligation: $1,349,853,665

Actual Outlays: $442,582,431

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES PROCEDURES NOT USED

Cost or Pricing Data: NO

Timeline